1: Gendron F, Grasser M, Le Guennic B. Near-infrared circular dichroism of the ytterbium DOTMA complex: an ab initio investigation. Phys Chem Chem Phys. 2022 Mar 2;24(9):5404-5410. doi: 10.1039/d1cp01675j. PMID: 35170600. 2: Woods M, Payne KM, Valente EJ, Kucera BE, Young VG Jr. Crystal Structures of DOTMA Chelates from Ce3+ to Yb3+ : Evidence for a Continuum of Metal Ion Hydration States. Chemistry. 2019 Jul 25;25(42):9997-10005. doi: 10.1002/chem.201902068. Epub 2019 Jul 3. PMID: 31121070; PMCID: PMC6700027. 3: Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017 May 28;254:55-64. doi: 10.1016/j.jconrel.2017.03.386. Epub 2017 Mar 24. PMID: 28347807. 4: Kumas C, Fernando WS, Zhao P, Regueiro-Figueroa M, Kiefer GE, Martins AF, Platas-Iglesias C, Sherry AD. Unexpected Changes in the Population of Coordination Isomers for the Lanthanide Ion Complexes of DOTMA-Tetraglycinate. Inorg Chem. 2016 Sep 19;55(18):9297-305. doi: 10.1021/acs.inorgchem.6b01390. Epub 2016 Sep 7. PMID: 27603690; PMCID: PMC5221692. 5: Webber BC, Woods M. Structural analysis of isomeric europium(III) chelates of NB-DOTMA. Inorg Chem. 2012 Aug 6;51(15):8576-82. doi: 10.1021/ic3011597. Epub 2012 Jul 18. PMID: 22809081. 6: Aime S, Botta M, Garda Z, Kucera BE, Tircso G, Young VG, Woods M. Properties, solution state behavior, and crystal structures of chelates of DOTMA. Inorg Chem. 2011 Sep 5;50(17):7955-65. doi: 10.1021/ic2012827. Epub 2011 Aug 5. PMID: 21819052; PMCID: PMC3204394. 7: Matsumoto M, Kishikawa R, Kurosaki T, Nakagawa H, Ichikawa N, Hamamoto T, To H, Kitahara T, Sasaki H. Hybrid vector including polyethylenimine and cationic lipid, DOTMA, for gene delivery. Int J Pharm. 2008 Nov 3;363(1-2):58-65. doi: 10.1016/j.ijpharm.2008.07.010. Epub 2008 Jul 18. PMID: 18687391. 8: Gaucheron J, Santaella C, Vierling P. Transfection with fluorinated lipoplexes based on fluorinated analogues of DOTMA, DMRIE and DPPES. Biochim Biophys Acta. 2002 Aug 31;1564(2):349-58. doi: 10.1016/s0005-2736(02)00469-8. PMID: 12175917. 9: Ren T, Song YK, Zhang G, Liu D. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther. 2000 May;7(9):764-8. doi: 10.1038/sj.gt.3301153. PMID: 10822303. 10: Wollenberg B, Kastenbauer, Mundl H, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Löhrs, Naujoks K, Rollston R. Gene therapy --phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther. 1999 Jan 1;10(1):141-7. doi: 10.1089/10430349950019273. PMID: 10022539. 11: Konopka K, Davis BR, Düzgüneş N. HIV-1 infection of a non-CD4-expressing variant of HUT-78 cells: lack of inhibition by Leu3A antibodies and enhancement by cationic DOTMA liposomes. Adv Exp Med Biol. 1991;300:97-110. doi: 10.1007/978-1-4684-5976-0_7. PMID: 1781348.

C42H84CLNO2

670.589

669.62

C, 75.23; H, 12.63; Cl, 5.29; N, 2.09; O, 4.77

104162-48-3

104162-48-3 (Z-isomer chloride);122342-03-4 (Z-isomer cation);104872-42-6 (E-isomer chloride);717090-94-3 (E-isomer cation);

CCCCCCCC/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\CCCCCCCC)C[N+](C)(C)C.[Cl-]

LDGWQMRUWMSZIU-LQDDAWAPSA-M

InChI=1S/C42H84NO2.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-44-41-42(40-43(3,4)5)45-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,42H,6-19,24-41H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;

N,N,N-trimethyl-2,3-bis(((Z)-octadec-9-en-1-yl)oxy)propan-1-aminium chloride

DOTMA; 1,2-di-O-octadecenyl-3-trimethylammonium propane

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。